Serveur d'exploration Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.

Identifieur interne : 000430 ( PubMed/Corpus ); précédent : 000429; suivant : 000431

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.

Auteurs : Syed Faraz Ahmed ; Ahmed A. Quadeer ; Matthew R. Mckay

Source :

RBID : pubmed:32106567

Abstract

The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.

DOI: 10.3390/v12030254
PubMed: 32106567

Links to Exploration step

pubmed:32106567

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.</title>
<author>
<name sortKey="Ahmed, Syed Faraz" sort="Ahmed, Syed Faraz" uniqKey="Ahmed S" first="Syed Faraz" last="Ahmed">Syed Faraz Ahmed</name>
<affiliation>
<nlm:affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Quadeer, Ahmed A" sort="Quadeer, Ahmed A" uniqKey="Quadeer A" first="Ahmed A" last="Quadeer">Ahmed A. Quadeer</name>
<affiliation>
<nlm:affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mckay, Matthew R" sort="Mckay, Matthew R" uniqKey="Mckay M" first="Matthew R" last="Mckay">Matthew R. Mckay</name>
<affiliation>
<nlm:affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32106567</idno>
<idno type="pmid">32106567</idno>
<idno type="doi">10.3390/v12030254</idno>
<idno type="wicri:Area/PubMed/Corpus">000430</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000430</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.</title>
<author>
<name sortKey="Ahmed, Syed Faraz" sort="Ahmed, Syed Faraz" uniqKey="Ahmed S" first="Syed Faraz" last="Ahmed">Syed Faraz Ahmed</name>
<affiliation>
<nlm:affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Quadeer, Ahmed A" sort="Quadeer, Ahmed A" uniqKey="Quadeer A" first="Ahmed A" last="Quadeer">Ahmed A. Quadeer</name>
<affiliation>
<nlm:affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Mckay, Matthew R" sort="Mckay, Matthew R" uniqKey="Mckay M" first="Matthew R" last="Mckay">Matthew R. Mckay</name>
<affiliation>
<nlm:affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Viruses</title>
<idno type="eISSN">1999-4915</idno>
<imprint>
<date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="In-Process" Owner="NLM">
<PMID Version="1">32106567</PMID>
<DateRevised>
<Year>2020</Year>
<Month>03</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1999-4915</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>12</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2020</Year>
<Month>02</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Viruses</Title>
<ISOAbbreviation>Viruses</ISOAbbreviation>
</Journal>
<ArticleTitle>Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">E254</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/v12030254</ELocationID>
<Abstract>
<AbstractText>The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ahmed</LastName>
<ForeName>Syed Faraz</ForeName>
<Initials>SF</Initials>
<Identifier Source="ORCID">0000-0002-6086-0307</Identifier>
<AffiliationInfo>
<Affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Quadeer</LastName>
<ForeName>Ahmed A</ForeName>
<Initials>AA</Initials>
<AffiliationInfo>
<Affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McKay</LastName>
<ForeName>Matthew R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>16204519</GrantID>
<Agency>Research Grants Council, University Grants Committee</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>02</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Viruses</MedlineTA>
<NlmUniqueID>101509722</NlmUniqueID>
<ISSNLinking>1999-4915</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="Y">2019 novel coronavirus</Keyword>
<Keyword MajorTopicYN="Y">2019-nCoV</Keyword>
<Keyword MajorTopicYN="Y">B cell epitopes</Keyword>
<Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Coronavirus</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV</Keyword>
<Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="Y">T cell epitopes</Keyword>
<Keyword MajorTopicYN="Y">vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2020</Year>
<Month>02</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2020</Year>
<Month>02</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2020</Year>
<Month>02</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>2</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>2</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2020</Year>
<Month>2</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32106567</ArticleId>
<ArticleId IdType="pii">v12030254</ArticleId>
<ArticleId IdType="doi">10.3390/v12030254</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000430 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000430 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32106567
   |texte=   Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:32106567" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Fri Mar 27 18:14:15 2020. Site generation: Sun Jan 31 15:15:08 2021